NO-dependent endothelial dysfunction in type II diabetes is aggravated by dyslipidemia and hypertension, but can be restored by angiotensin-converting enzyme inhibition and weight loss

Journal of Vascular Research

Volumn 50, Issue 6, 2013, Pages 486-497

  Nevelsteen, Ines ^a   Van Den Bergh, An ^a   Van Der Mieren, Gerry ^a   Vanderper, Annelies ^a   Mubagwa, Kanigula ^a   Bult, Hidde ^b   Herijgers, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Angiotensin converting enzyme inhibition; Diabetes mellitus type II; Endothelial dysfunction; Metabolic syndrome; Weight loss

Indexed keywords

CAPTOPRIL; LEPTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NITRIC OXIDE; ACETYLCHOLINE; BRADYKININ; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PHENYLEPHRINE; TRIACYLGLYCEROL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CALORIC RESTRICTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; ENZYME INHIBITION; GENOTYPE; IN VIVO STUDY; KNOCKOUT MOUSE; LOW CALORY DIET; METABOLIC SYNDROME X; MOUSE; MOUSE MUTANT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE; THORACIC AORTA; VASCULAR RING; VASOCONSTRICTION; VASODILATATION; WEIGHT REDUCTION; ALPHA ADRENERGIC STIMULATION; ARTERY DILATATION; ARTERY ENDOTHELIUM; CHOLESTEROL BLOOD LEVEL; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HYPERTENSION; MALE; METABOLIC PARAMETERS; MOUSE MODEL; PHENOTYPE; VASOMOTOR REFLEX;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CALORIC RESTRICTION; CAPTOPRIL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; HYPERTENSION; LEPTIN; LIPIDS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, OBESE; NITRIC OXIDE; RECEPTORS, LDL; TIME FACTORS; VASODILATION; VASODILATOR AGENTS; WEIGHT LOSS;

EID: 84886735427     PISSN: 10181172     EISSN: 14230135     Source Type: Journal    
DOI: 10.1159/000355221     Document Type: Article

References (64)

1. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM: Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130: 963-974. (Pubitemid 30453529)
2. Schalkwijk CG, Stehouwer CD: Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 2005; 109: 143-159. (Pubitemid 41117297)
3. Okon EB, Szado T, Laher I, McManus B, van Breemen C: Augmented contractile response of vascular smooth muscle in a diabetic mouse model. J Vasc Res 2003; 40: 520-530. (Pubitemid 38186462)
4. Winters B, Mo Z, Brooks-Asplund E, Kim S, Shoukas A, Li D, Nyhan D, Berkowitz DE: Reduction of obesity, as induced by leptin, reverses endothelial dysfunction in obese (Lep(ob)) mice. J Appl Physiol 2000; 89: 2382-2390.
5. Miike T, Kunishiro K, Kanda M, Azukizawa S, Kurahashi K, Shirahase H: Impairment of endothelium-dependent ACh-induced relaxation in aorta of diabetic db/db mice - possible dysfunction of receptor and/or receptor-G protein coupling. Naunyn Schmiedebergs Arch Pharmacol 2008; 377: 401-410.
6. Balasubramanyam M, Balaji RA, Subashini B, Mohan V: Evidence for mechanistic alterations of Ca 2+ homeostasis in type 2 diabetes mellitus. Int J Exp Diabetes Res 2001; 1: 275-287.
7. Levy J, Gavin JR 3rd, Sowers JR: Diabetes mellitus: a disease of abnormal cellular calcium metabolism? Am J Med 1994; 96: 260-273. (Pubitemid 24099226)
8. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C: Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438. (Pubitemid 38133916)
9. Van den Bergh A, Vanderper A, Vangheluwe P, Desjardins F, Nevelsteen I, Verreth W, Wuytack F, Holvoet P, Flameng W, Balligand JL, Herijgers P: Dyslipidaemia in type II diabetic mice does not aggravate contractile impairment but increases ventricular stiffness. Cardiovasc Res 2008; 77: 371-379 . (Pubitemid 351197628)
10. Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, De Angelis N, Ghezzi P, Latini R, Masson S: Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 2006; 79: 121-129. (Pubitemid 43737057)
11. Keidar S, Attias J, Coleman R, Wirth K, Schölkens B, Hayek T: Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J Cardiovasc Pharmacol 2000; 35: 64-72. (Pubitemid 30032895)
12. Buikema H, Monnink SH, Tio RA, Crijns HJ, de Zeeuw D, van Gilst WH: Comparison of zofenopril and lisinopril to study the role of the sulfhydryl-group in improvement of endothelial dysfunction with ACE-inhibitors in experimental heart failure. Br J Pharmacol 2000; 130: 1999-2007. (Pubitemid 30655814)
13. Khan BV, Sola S, Lauten WB, Natarajan R, Hooper WC, Menon RG, Lerakis S, Helmy T: Quinapril, an ACE inhibitor, reduces markers of oxidative stress in the metabolic syndrome. Diabetes Care 2004; 27: 1712-1715. (Pubitemid 38857449)
14. Sasaki S, Higashi Y, Nakagawa K, Kimura M, Noma K, Sasaki S, Hara K, Matsuura H, Goto C, Oshima T, Chayama K: A low-calorie diet improves endothelium-dependent vasodilation in obese patients with essential hypertension. Am J Hypertens 2002; 15: 302-309. (Pubitemid 34408968)
15. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D: Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Circulation 2002; 105: 804-809. (Pubitemid 34174919)
16. Lee S, Park Y, Zhang C: Exercise training prevents coronary endothelial dysfunction in type 2 diabetic mice. Am J Biomed Sci 2011; 3: 241-252.
17. Lee S, Park Y, Dellsperger KC, Zhang C: Exercise training improves endothelial function via adiponectin-dependent and independent pathways in type 2 diabetic mice. Am J Physiol Heart Circ Physiol 2011; 301:H306-H314.
18. Mertens A, Verhamme P, Bielicki JK, Phillips MC, Quarck R, Verreth W, Stengel D, Ninio E, Navab M, Mackness B, Mackness M, Holvoet P: Increased low-density lipoprotein oxidation and impaired high-density lipoprotein antioxidant defense are associated with increased macrophage homing and atherosclerosis in dyslipidemic obese mice: LCAT gene transfer decreases atherosclerosis. Circulation 2003; 107: 1640-1646. (Pubitemid 36397333)
19. Verreth W, De Keyzer D, Pelat M, Verhamme P, Ganame J, Bielicki JK, Mertens A, Quarck R, Benhabilès N, Marguerie G, Mackness B, Mackness M, Ninio E, Herregods MC, Balligand JL, Holvoet P: Weight-loss-associated induction of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator- activated receptor-gamma correlate with reduced atherosclerosis and improved cardiovascular function in obese insulin-resistant mice. Circulation 2004; 110: 3259-3269. (Pubitemid 39525075)
20. Wichi RB, Farah V, Chen Y, Irigoyen MC, Morris M: Deficiency in angiotensin AT1a receptors prevents diabetes-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2007; 292:R1184-R1189. (Pubitemid 46377083)
21. Van Hove CE, Van der Donckt C, Herman AG, Bult H, Fransen P: Vasodilator efficacy of nitric oxide depends on mechanisms of intracellular calcium mobilization in mouse aortic smooth muscle cells. Br J Pharmacol 2009; 158: 920-930.
22. Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995; 377: 239-242.
23. Wölfle SE, de Wit C: Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. J Vasc Res 2005; 42: 475-482. (Pubitemid 41527602)
24. Kim JA, Montagnani M, Koh KK, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006; 113: 1888-1904. (Pubitemid 43739401)
25. Liang CP, Tall AR: Transcriptional profiling reveals global defects in energy metabolism, lipoprotein, and bile acid synthesis and transport with reversal by leptin treatment in ob/ob mouse liver. J Biol Chem 2001; 276: 49066- 49076.
26. Feron O, Dessy C, Desager JP, Balligand JL: Hydroxy-methylglutaryl- coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance. Circulation 2001; 103: 113-118. (Pubitemid 32050445)
27. Kugiyama K, Kerns SA, Morrisett JD, Roberts R, Henry PD: Impairment of endotheliumdependent arterial relaxation by lysolecithin in modified low-density lipoproteins. Nature 1990; 344: 160-162. (Pubitemid 20094133)
28. Puddu P, Puddu GM, Zaca F, Muscari A: Endothelial dysfunction in hypertension (review). Acta Cardiol 2000; 55: 221-232.
29. Cai H, Harrison DG: Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-844 .
30. Heitsch H: Bradykinin B2 receptor as a potential therapeutic target. Drug News Perspect 2000; 13: 213-225.
31. Chlopicki S, Kozlovski VI, Lorkowska B, Drelicharz L, Gebska A: Compensation of endothelium- dependent responses in coronary circulation of eNOS-deficient mice. J Cardiovasc Pharmacol 2005; 46: 115-123. (Pubitemid 40917787)
32. Rodriguez JA, De la Cerda P, Collyer E, Decap V, Vio CP, Velarde V: Cyclooxygenase-2 induction by bradykinin in aortic vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2006; 290:H30-H36.
33. Schönbeck U, Sukhova GK, Graber P, Coulter S, Libby P: Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol 1999; 155: 1281-1291. (Pubitemid 29488935)
34. Gendron ME, Thorin-Trescases N, Villeneuve L, Thorin E: Aging associated with mild dyslipidemia reveals that COX-2 preserves dilation despite endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007; 292:H451-H458. (Pubitemid 46105209)
35. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286: 954-959. (Pubitemid 33010342)
36. Feng L, Xia Y, Garcia GE, Hwang D, Wilson CB: Involvement of reactive oxygen intermediates in cyclooxygenase-2 expression induced by interleukin-1, tumor necrosis factor- alpha, and lipopolysaccharide. J Clin Invest 1995; 95: 1669-1675.
37. Fransen P, Van Assche T, Guns PJ, Van Hove CE, De Keulenaer GW, Herman AG, Bult H: Endothelial function in aorta segments of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Pflügers Arch 2008; 455: 811-818. (Pubitemid 350265620)
38. Guo Z, Su W, Allen S, Pang H, Daugherty A, Smart E, Gong MC: COX-2 up-regulation and vascular smooth muscle contractile hyperreactivity in spontaneous diabetic db/db mice. Cardiovasc Res 2005; 67: 723-735. (Pubitemid 41033368)
39. Liu Y, Gutterman DD: The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol 2002; 38: 43-49. (Pubitemid 36398289)
40. Phillips MI, Speakman EA, Kimura B: Levels of angiotensin and molecular biology of the tissue renin angiotensin systems. Regul Pept 1993; 43: 1-20.
41. Frederich RC Jr, Kahn BB, Peach MJ, Flier JS: Tissue-specific nutritional regulation of angiotensinogen in adipose tissue. Hypertension 1992; 19: 339-344.
42. Tesfamariam B, Cohen RA: Free radicals mediate endothelial cell dysfunction caused by elevated glucose. Am J Physiol 1992; 263: H321-H326.
43. Sodhi CP, Kanwar YS, Sahai A: Hypoxia and high glucose upregulate AT1 receptor expression and potentiate ANG II-induced proliferation in VSM cells. Am J Physiol Heart Circ Physiol 2003; 284:H846-H852. (Pubitemid 36228231)
44. Wong WT, Tian XY, Xu A, Ng CF, Lee HK, Chen ZY, Au CL, Yao X, Huang Y: Angiotensin II type 1 receptor-dependent oxidative stress mediates endothelial dysfunction in type 2 diabetic mice. Antioxid Redox Signal 2010; 13: 757-768.
45. Nickenig G, Sachinidis A, Seewald S, Böhm M, Vetter H: Influence of oxidized low-density lipoprotein on vascular angiotensin II receptor expression. J Hypertens Suppl 1997; 15:S27-S30.
46. Oak JH, Cai H: Attenuation of angiotensin II signaling recouples eNOS and inhibits nonendothelial NOX activity in diabetic mice. Diabetes 2007; 56: 118-126.
47. Taguchi K, Kobayashi T, Takenouchi Y, Matsumoto T, Kamata K: Angiotensin II causes endothelial dysfunction via the GRK2/Akt/ eNOS pathway in aortas from a murine type 2 diabetic model. Pharmacol Res 2011; 64: 535-546.
48. Tabbi-Anneni I, Buchanan J, Cooksey RC, Abel ED: Captopril normalizes insulin signaling and insulin-regulated substrate metabolism in obese (ob/ob) mouse hearts. Endocrinology 2008; 149: 4043-4050.
49. Robertson JI, Tillman DM: Converting enzyme inhibitors in the treatment of hypertension. J Cardiovasc Pharmacol 1987; 10(suppl 7): S43-S48.
50. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ, American Heart Association, American Diabetes Association: Primary prevention of cardiovascular disease in people with diabetes mellitus. A scientific statement from the American Heart Association and the American Diabetes Association. Circulation 2007; 115: 114-126. (Pubitemid 46058619)
51. Keidar S: Angiotensin, LDL peroxidation and atherosclerosis. Life Sci 1998; 63: 1-11. (Pubitemid 28293568)
52. Pollare T, Lithell H, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989; 321: 868-873. (Pubitemid 19238619)
53. Sachinidis A, Locher R, Vetter W: Generation of intracellular signals by low density lipoprotein is independent of the classical LDL receptor. Am J Hypertens 1991; 4: 274-279.
54. Sachinidis A, Mendgen T, Locher R, Brunner C, Vetter W: Novel activities for low density lipoprotein in vascular smooth muscle cells. Hypertension 1990; 15: 704-711. (Pubitemid 20189445)
55. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Klibaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B: Angiotensin- converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 258-265, erratum p 1490. (Pubitemid 26266107)
56. Pretorius M, Rosenbaum D, Vaughan DE, Brown NJ: Angiotensin-converting enzyme inhibition increases human vascular tissuetype plasminogen activator release through endogenous bradykinin. Circulation 2003; 107: 579-585. (Pubitemid 36176808)
57. Brown NJ, Ryder D, Gainer JV, Morrow JD, Nadeau J: Differential effects of angiotensin converting enzyme inhibitors on the vasodepressor and prostacyclin responses to bradykinin. J Pharmacol Exp Ther 1996; 279: 703- 712. (Pubitemid 27166842)
58. Décarie A, Raymond P, Gervais N, Couture R, Adam A: Serum interspecies differences in metabolic pathways of bradykinin and [des- Arg9]BK: influence of enalaprilat. Am J Physiol 1996; 271:H1340-H1347.
59. Tiefenbacher CP, Friedrich S, Bleeke T, Vahl C, Chen X, Niroomand F: ACE inhibitors and statins acutely improve endothelial dysfunction of human coronary arterioles. Am J Physiol Heart Circ Physiol 2004; 286:H1425-H1432. (Pubitemid 38381151)
60. Bergholm R, Tiikkainen M, Vehkavaara S, Tamminen M, Teramo K, Rissanen A, Yki- Järvinen H: Lowering of LDL cholesterol rather than moderate weight loss improves endothelium- dependent vasodilatation in obese women with previous gestational diabetes. Diabetes Care 2003; 26: 1667-1672. (Pubitemid 36929101)
61. Moien-Afshari F, Ghosh S, Elmi S, Rahman MM, Sallam N, Khazaei M, Kieffer TJ, Brownsey RW, Laher I: Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice. Diabetologia 2008; 51: 1327-1337
62. erratum 2009; 52: 181.
63. Poirier P, Eckel RH: Obesity and cardiovascular disease. Curr Atheroscler Rep 2002; 4: 448- 453.
64. Ren J: Leptin and hyperleptinemia - from friend to foe for cardiovascular function. J Endocrinol 2004; 181: 1-10. (Pubitemid 38584659)